{"filing":{"accession_number":"0001213900-26-098205","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304939-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026098205/ea0304939-6k_canfite.htm"},"events":[{"id":32168,"run_id":29550,"accession_number":"0001213900-26-098205","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the publication of a peer-reviewed case report describing clinical improvement in a decompensated cirrhosis patient treated with Namodenoson, one of Can-Fite's lead drug candidates. The patient experienced resolution of ascites, regression of esophageal varices, and remained stable for 28 months before successful liver transplantation. While this is a single-patient case report rather than a formal clinical trial result, it represents a material operational/clinical milestone for the company's drug development pipeline, supporting further evaluation of Namodenoson in advanced liver disease and potentially influencing investor assessment of the company's clinical progress.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35279,"accession_number":"0001213900-26-098205","item_number":"EX-99.1","item_title":"ea030493901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the publication of a peer-reviewed case report describing clinical improvement in a decompensated cirrhosis patient treated with Namodenoson, one of Can-Fite's lead drug candidates. The patient experienced resolution of ascites, regression of esophageal varices, and remained stable for 28 months before successful liver transplantation. While this is a single-patient case report rather than a formal clinical trial result, it represents a material operational/clinical milestone for the company's drug development pipeline, supporting further evaluation of Namodenoson in advanced liver disease and potentially influencing investor assessment of the company's clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:03:40.602656+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35279,"accession_number":"0001213900-26-098205","item_number":"EX-99.1","item_title":"ea030493901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the publication of a peer-reviewed case report describing clinical improvement in a decompensated cirrhosis patient treated with Namodenoson, one of Can-Fite's lead drug candidates. The patient experienced resolution of ascites, regression of esophageal varices, and remained stable for 28 months before successful liver transplantation. While this is a single-patient case report rather than a formal clinical trial result, it represents a material operational/clinical milestone for the company's drug development pipeline, supporting further evaluation of Namodenoson in advanced liver disease and potentially influencing investor assessment of the company's clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:03:40.602656+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-09"}]}